{"name":"Genzum Life Sciences","slug":"genzum-life-sciences","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFB5bjhfamdueGFrd0o1TFViMnpXTjIyYlNyR0p5N1B3bWl5cmFNX29aNnNtUkpmd3RpbVdZTDBtbE9MenJxVEFYai1Xbm9zY2lTdjlwSkRkR0xjcUhZM3RLYzJHcldxSmVNYmM5aWdSNkVRUQ?oc=5","date":"2022-05-27","type":"patent","source":"Pharmacy Times","summary":"Generic Product News: May 2022 - Pharmacy Times","headline":"Generic Product News: May 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFA2aDBJUTRaNkVDTDFlcG80bkVyOGVWVUtZamJpVks0b2VfZ2l3ZXhoLXg4akI1M2R0c1EyeU0zazhLZVRJcUFPa1FjR3pPT2hackU0bEhwRXN0Zlh5MWI5dWZsOHVJMGIxblF3NjJpRQ?oc=5","date":"2022-03-04","type":"patent","source":"Drug Store News","summary":"Xiromed, Genzum unveil generic Naftin - Drug Store News","headline":"Xiromed, Genzum unveil generic Naftin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1aWFFOV1BqOS1BaV9Rbm9EUWNhUld3dDg5ckdtMy1zcVhHTmVUYk9LQTJHRHpMRjhkVV9IaHNDMS1GdmNUN1NjamRvZmxNY2RZOWxxSjFUTkhuNExLRFc2Q1MyamY1elh1WmdZ?oc=5","date":"2014-01-09","type":"earnings","source":"C-Suite Quarterly","summary":"Chris Achar: A “Sip” Off the Ol’ Block - C-Suite Quarterly","headline":"Chris Achar: A “Sip” Off the Ol’ Block - C","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}